Mounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study finds

Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup